Pressemitteilungen von Raptor Pharmaceutical Corp.

Letzten 10 Pressemitteilungen

• DGAP-News: Raptor Pharmaceutical lizenziert geistiges Eigentum der McGill University in Verbindung mit Malaria
  Raptor Pharmaceutical Corp. 29.05.2012 19:43 --------------------------------------------------------------------------- NOVATO, Kalifornien, USA, 2012-05-29 19:43 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat bekanntgegeben, dass das Unternehmen die exklusiven Rechte am geistigen Eigentum in Verbindung mit Cysteamin und zugehorigen Substanzen fur die potenzielle Behandlung von parasitaren Erkrankungen, wie z. B. Malaria, von der McGi ...
  
  
• DGAP-News: Raptor Pharmaceutical Licenses Intellectual Property Related to Malaria From McGill University
  Raptor Pharmaceutical Corp. 29.05.2012 13:30 --------------------------------------------------------------------------- NOVATO, Calif., 2012-05-29 13:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced that the Company has acquired exclusive rights to intellectual property related to cysteamine and related compounds in the potential treatment of parasitic diseases, including malaria, from McGill University ('McGill') in Montreal, Canad ...
  
  
• DGAP-News: Raptor Pharmaceutical kundigt Veroffentlichung der Ergebnisse der klinischen Phase-III-Studie im Clinical Journal of the American Society of Nephrology an
  Raptor Pharmaceutical Corp. 04.05.2012 20:20 --------------------------------------------------------------------------- Bietet neueste Informationen zum Programm fur nephropathische Cystinose NOVATO, Kalifornien, 2012-05-04 20:19 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat die Online-Veroffentlichung eines Artikels mit dem Titel 'A Randomized Controlled Crossover Trial with a Delayed Release Cysteamine Bitartrate in Nephropathic C ...
  
  
• DGAP-News: Raptor Pharmaceutical Announces Publication of Phase 3 Results in the Clinical Journal of the American Society of Nephrology
  Raptor Pharmaceutical Corp. 03.05.2012 19:15 --------------------------------------------------------------------------- Provides an Update on the Nephropathic Cystinosis Program NOVATO, Calif., 2012-05-03 19:15 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced the online publication of an article titled, 'A Randomized Controlled Crossover Trial with a Delayed Release Cysteamine Bitartrate in Nephropathic Cystinosis: Effectiveness on WB ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert bei zwei Investorenkonferenzen
  Raptor Pharmaceutical Corp. 03.05.2012 15:37 --------------------------------------------------------------------------- NOVATO, Kalifornien, 2012-05-03 15:37 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass sein CEO Christopher M. Starr, Ph.D., bei zwei im Mai stattfindenden Investorenkonferenzen einen Uberblick uber das Unternehmen geben wird. Der Prasentationsplan fur die Konferenzen lautet wie folgt: Deutsche B ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at Two Upcoming Investor Conferences
  Raptor Pharmaceutical Corp. 03.05.2012 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2012-05-03 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., Chief Executive Officer of Raptor, will present an overview of the Company at two investor conferences in May. The conference presentation schedule is as follows: Deutsche Bank 37th Annual Healt ...
  
  
• DGAP-News: Raptor Pharmaceutical gibt Verkaufsprogramm fur Stammaktien auf dem freien Markt bekannt
  Raptor Pharmaceutical Corp. 01.05.2012 18:16 --------------------------------------------------------------------------- NOVATO, Kalif., 2012-05-01 18:16 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass es am 30. April 2012 eine Verkaufsvereinbarung mit Cowen and Company, LLC ('Cowen') fur den Verkauf von Stammaktien am freien Markt ('At-the-Market (ATM)') getroffen hat. Im Rahmen dieser Vereinbarung kann Raptor nach ...
  
  
• DGAP-News: Raptor Pharmaceutical Announces At-the-Market Common Stock Sales Program
  Raptor Pharmaceutical Corp. 01.05.2012 12:00 --------------------------------------------------------------------------- NOVATO, Calif., 2012-05-01 12:00 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that it has entered into an 'At-the-Market' ('ATM') Sales Agreement, dated April 30, 2012, with Cowen and Company, LLC ('Cowen'), under which Raptor may, at its discretion, sell its common stock with a sales value of up to a maxim ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. halt Vortrag bei der Day of Hope Family Conference der Cystinosis Research Foundation
  Raptor Pharmaceutical Corp. 12.04.2012 18:07 --------------------------------------------------------------------------- NOVATO, Kalifornien, 2012-04-12 18:07 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute angekundigt, dass Raptors President Ted Daley neueste Informationen zu seinem Prufmedikament, Cysteaminbitartrat-Kapseln mit verzogerter Freisetzung (RP103) fur die potenzielle Behandlung von nephropathischer Cystinose, bei der ...
  
  
• DGAP-News: Raptor Pharmaceutical erhalt Erteilungsbescheid fur wichtige europaische Patentanmeldungen zum Schutz seines Cysteamin-Portfolios
  Raptor Pharmaceutical Corp. 12.04.2012 18:06 --------------------------------------------------------------------------- Patentanspruche decken den Einsatz von Cysteamin mit verzogerter Wirkstofffreisetzung bei Cystinose ab NOVATO, Kalifornien, 2012-04-12 18:05 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute bekannt gegeben, dass das Europaische Patentamt einen Erteilungsbescheid fur ein wichtiges Patent ausgegeben hat, das den ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at Cystinosis Research Foundation Day of Hope Family Conference
  Raptor Pharmaceutical Corp. 12.04.2012 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2012-04-12 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that Ted Daley, President, will present an update on its investigational drug candidate, Cysteamine Bitartrate Delayed-Release Capsules (RP103), for the potential treatment of nephropathic cystinosis at the Cystinosis Research Found ...
  
  
• DGAP-News: Raptor Pharmaceutical Receives Notices of Allowance for Key European Patent Applications Protecting Its Cysteamine Portfolio
  Raptor Pharmaceutical Corp. 12.04.2012 12:30 --------------------------------------------------------------------------- Patent Claims Cover Use of Delayed-Release Cysteamine in Cystinosis NOVATO, Calif., 2012-04-12 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that the European Patent Office has issued a Notice of Allowance for a key patent covering the use of enteric-coated, delayed-release ('DR') oral formulations of ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. reicht Antrag auf Arzneimittelzulassung von RP103 zur potenziellen Behandlung von nephropathischer Cystinose ein
  Raptor Pharmaceutical Corp. 02.04.2012 17:39 --------------------------------------------------------------------------- NOVATO, Kalif., 2012-04-02 17:38 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass es einen Antrag auf Arzneimittelzulassung (New Drug Application, 'NDA') bei der U.S. Food and Drug Administration ('FDA') eingereicht hat, um die Marktzulassung fur das Prufmedikament RP103 (Cysteaminbitartrat-Kapseln ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Submits New Drug Application for RP103 for the Potential Treatment of Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 30.03.2012 17:44 --------------------------------------------------------------------------- NOVATO, Calif., 2012-03-30 17:44 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) announced that it submitted a New Drug Application ('NDA') to the U.S. Food and Drug Administration ('FDA') seeking approval to market its investigational drug candidate, Cysteamine Bitartrate Delayed-release Capsules (RP103), for the potential tre ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. gibt die Ernennung von Henk Doude van Troostwijk zum General Manager of European Commercial Operations bekannt
  Raptor Pharmaceutical Corp. 28.03.2012 16:56 --------------------------------------------------------------------------- Raptor richtet europaische Zentrale in den Niederlanden ein NOVATO, Kalifornien, 2012-03-28 16:56 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' bzw. das 'Unternehmen') (Nasdaq:RPTP), hat die Ernennung von Henk Doude van Troostwijk als General Manager of European Commercial Operations mit Wirkung zum 15. April 2012 bekannt gegeben. Henk Doude van Troostwijk ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Announces the Appointment of Henk Doude van Troostwijk as General Manager of European Commercial Operations
  Raptor Pharmaceutical Corp. 28.03.2012 12:30 --------------------------------------------------------------------------- Raptor Establishes European Headquarters in the Netherlands NOVATO, Calif., 2012-03-28 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced the appointment of Henk Doude van Troostwijk as its General Manager of European Commercial Operations, effective April 15, 2012. Mr. Doude van Troostwijk will be responsible fo ...
  
  
• DGAP-News: Press Release: Raptor Pharmaceutical Corp.
  Raptor Pharmaceutical Corp. 26.03.2012 16:02 --------------------------------------------------------------------------- Raptor Pharmaceutical Corp. gibt EMA-Validierung des Antrags auf Genehmigung fur das Inverkehrbringen von RP103 zur Behandlung von nephropathischer Cystinose bekannt Einreichung des NDA-Zulassungsantrags bei der FDA ist fur Marz 2012 geplant NOVATO, Kalifornien, USA, 26. Marz 2012 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:R ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Announces EMA Validation of Marketing Authorization Application for RP103 for the Treatment of Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 26.03.2012 12:30 --------------------------------------------------------------------------- FDA NDA Submission Planned in March 2012 NOVATO, Calif., 2012-03-26 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced that the European Medicines Agency ('EMA') has determined that Raptor's Marketing Authorization Application ('MAA') for its investigational drug candidate, RP103 for the potential treatment of ne ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. fur den Handel auf dem NASDAQ Global Market hochgestuft
  Raptor Pharmaceutical Corp. 02.03.2012 13:24 --------------------------------------------------------------------------- Unternehmen stellt sich auf der 32nd Annual Health Care Conference der Cowen Group vor NOVATO, Kalifornien, 2012-03-02 13:24 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute angekundigt, dass das Unternehmen fur den Handel auf dem NASDAQ Global Market hochgestuft wurde. Anteile der Stammaktien von Raptor werden ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Upgraded to Trade on the NASDAQ Global Market
  Raptor Pharmaceutical Corp. 02.03.2012 12:30 --------------------------------------------------------------------------- Company to Present at the 32nd Annual Cowen Health Care Conference NOVATO, Calif., 2012-03-02 12:30 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that the Company has been upgraded to trade on the NASDAQ Global Market. Shares of Raptor's common stock began trading on the NASDAQ Global Market on February 29, 20 ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert bei drei Investorenkonferenzen
  Raptor Pharmaceutical Corp. 10.02.2012 14:35 --------------------------------------------------------------------------- NOVATO, Kalifornien, 2012-02-10 14:35 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass sein CEO Christopher M. Starr, Ph.D., bei drei im Februar stattfindenden Investorenkonferenzen einen Uberblick uber das Unternehmen geben wird. Der Prasentationsplan fur die Konferenzen lautet wie folgt: L ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at Three Upcoming Investor Conferences
  Raptor Pharmaceutical Corp. 10.02.2012 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2012-02-10 12:30 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that its Chief Executive Officer, Christopher M. Starr, Ph.D., will present an overview of the Company at three investor conferences in February. The conference presentation schedule is as follows: Leerink Swann 2012 Global Health ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert auf der 30th Annual JP Morgan Healthcare Conference
  Raptor Pharmaceutical Corp. 05.01.2012 14:41 --------------------------------------------------------------------------- Raptor fuhrt offene Veranstaltung zur Diskussion des NASH-Programms und der anstehenden klinischen Phase-2b-Studie durch NOVATO, Kalif., 2012-01-05 14:41 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass Christopher M. Starr, Ph.D., CEO von Raptor, auf der 30th Annual JP Morgan Healthcare Conference ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at the 30th Annual JP Morgan Healthcare Conference
  Raptor Pharmaceutical Corp. 04.01.2012 22:39 --------------------------------------------------------------------------- Raptor Hosts Open Event to Discuss NASH Program and Upcoming Phase 2b Clinical Trial NOVATO, Calif., 2012-01-04 22:39 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive Officer, will present an overview of the Company at the 30th Annual JP Morgan Healthcar ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. aktualisiert Programm zu RP103 (DR Cysteamin) fur nephropathische Cystinose
  Raptor Pharmaceutical Corp. 21.12.2011 15:55 --------------------------------------------------------------------------- Auf dem besten Wege, im ersten Quartal 2012 Zulassungsantrage in den USA und in Europa zu stellen NOVATO, Kalifornien, 2011-12-21 15:55 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute eine Aktualisierung des Programms zu seiner Hauptforschungssubstanz, RP103, fur die mogliche Behandlung der nephropathischen Cys ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Provides Program Update on RP103 (DR Cysteamine) for Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 21.12.2011 12:30 --------------------------------------------------------------------------- On Track to File Marketing Applications in US and EU in the First Quarter of 2012 NOVATO, Calif., 2011-12-21 12:30 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) announced today a program update for its lead investigational compound, RP103 for the potential treatment of nephropathic cystinosis. RP103 is Raptor's proprietary, ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. press release
  Raptor Pharmaceutical Corp. 19.12.2011 19:20 --------------------------------------------------------------------------- Raptor Pharmaceutical Corp. unterzeichnet Vereinbarung mit dem NIDDK uber die Forschungs- und Entwicklungszusammenarbeit bei der klinischen Phase-2b-Studie zu RP104 (DR Cysteamin-Tabletten) bei nichtalkoholischer Steatohepatitis ('NASH') Voraussichtlicher Beginn der Phase-2b-Studie im ersten Quartal 2012 Unternehmen, das die NASH-Veranstaltung bei der JP Morgan Hea ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Signs Collaborative Research and Development Agreement With NIDDK on Phase 2b Clinical Trial of RP104 (DR Cysteamine Tablets) in Non-Alcoholic Steatohepatitis ('NASH')
  Raptor Pharmaceutical Corp. 19.12.2011 12:30 --------------------------------------------------------------------------- Phase 2b Trial Anticipated to Start in Q1 2012 Company to Host NASH Event at JP Morgan Healthcare Conference NOVATO, Calif., Dec. 19, 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced the signing of a cooperative research and development agreement ('CRADA') with the National Institute ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert auf der Oppenheimer 22nd Annual Healthcare Conference
  Raptor Pharmaceutical Corp. 13.12.2011 23:07 --------------------------------------------------------------------------- NOVATO, Kalif., 2011-12-13 23:07 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass Christopher M. Starr Ph.D., CEO von Raptor, auf der Oppenheimer 22nd Annual Healthcare Conference einen Uberblick uber das Unternehmen geben wird. Die Prasentation von Raptor wird im Waldorf=Astoria Hotel in New York C ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at the Oppenheimer 22nd Annual Healthcare Conference
  Raptor Pharmaceutical Corp. 13.12.2011 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2011-12-13 12:30 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that Christopher M. Starr, Ph.D., Raptor's Chief Executive Officer will present an overview of the Company at the Oppenheimer 22nd Annual Healthcare Conference. Raptor's presentation will take place at The Waldorf=Astoria Hotel in Ne ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert auf der Lazard Capital Markets 8th Annual Healthcare Conference
  Raptor Pharmaceutical Corp. 09.11.2011 20:40 --------------------------------------------------------------------------- NOVATO, Kalif., 2011-11-09 20:39 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass Ted Daley, President von Raptor, auf der Lazard Capital Markets 8th Annual Healthcare Conference einen Uberblick uber das Unternehmen geben wird. Die Prasentation von Raptor wird im The Pierre Hotel in New York City am ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at the Lazard Capital Markets 8th Annual Healthcare Conference
  Raptor Pharmaceutical Corp. 09.11.2011 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2011-11-09 12:30 CET (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that Ted Daley, President of Raptor will present an overview of the Company at the Lazard Capital Markets 8th Annual Healthcare Conference. Raptor's presentation will take place at The Pierre Hotel in New York City on Tuesday, Novem ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Release
  Raptor Pharmaceutical Corp. 26.10.2011 17:15 --------------------------------------------------------------------------- Raptor Pharmaceutical Corp. halt vorbereitende Besprechung zum Zulassungsantrag fur RP103 zur Behandlung nephropathischer Cystinose mit der FDA ab Unternehmen ist auf dem besten Weg zur Einreichung des Zulassungsantrags im 1. Quartal 2012 NOVATO, Kalif., 2011-10-26 17:06 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Holds Pre-NDA Meeting With FDA for RP103 for Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 25.10.2011 20:27 --------------------------------------------------------------------------- Company Remains on Track for NDA Submission in Q1 2012 NOVATO, Calif., 2011-10-25 20:27 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced today that the Company concluded a pre-New Drug Application ('NDA') meeting with the U.S. Food and Drug Administration ('FDA') related to its investigational drug candidate, RP103 ( ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. prasentiert auf der NewsMakers-Konferenz von BioCentury
  Raptor Pharmaceutical Corp. 13.10.2011 17:52 --------------------------------------------------------------------------- NOVATO, Kalif., 13. Oktober 2011 (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass Patrick Reichenberger, VP, Commercial Operations von Raptor, auf der 'NewsMakers in the Biotech Industry'-Konferenz 2011 von BioCentury einen Uberblick uber das Unternehmen geben wird. Die Prasentation von Raptor wird im Mi ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. to Present at JMP Securities Healthcare Conference
  Raptor Pharmaceutical Corp. 22.09.2011 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2011-09-22 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that Christopher M. Starr, Ph.D., co-founder and Chief Executive Officer of Raptor will present an overview of the Company at the JMP Securities Healthcare Conference. Raptor's presentation will take place at the St. Regis Hotel in ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Announces Closing of Public Offering of Common Stock
  Raptor Pharmaceutical Corp. 13.09.2011 19:05 --------------------------------------------------------------------------- NOVATO, Calif., 2011-09-13 19:05 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced the closing of its previously announced underwritten public offering of shares of its common stock at a price to the public of $4.00 per share. The shares sold in the offering included 10,000,000 shares of common stock plus an addi ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Announces Pricing of Public Offering of Common Stock
  Raptor Pharmaceutical Corp. 08.09.2011 15:47 --------------------------------------------------------------------------- NOVATO, Calif., 2011-09-08 15:46 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced the pricing of its previously announced underwritten public offering of 10,000,000 shares of its common stock at a price to the public of $4.00 per share. The net proceeds to the Company from this offering are expected to be approx ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp. Announces Proposed Public Offering of Common Stock
  Raptor Pharmaceutical Corp. 07.09.2011 22:39 --------------------------------------------------------------------------- NOVATO, Calif., 2011-09-07 22:39 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that it intends to offer and sell shares of its common stock, par value $0.001 per share, in an underwritten public offering. The Company also expects to grant the underwriters a 30-day option to purchase additional shares of commo ...
  
  
• DGAP-News: Raptor Pharmaceutical veranstaltet am Dienstag, den 26. Juli 2011 um 12 Uhr mittags EST Telefonkonferenz und Webcast zur Erorterung der Ergebnisse der klinischen Phase-III-Studie
  Raptor Pharmaceutical Corp. 27.07.2011 01:11 --------------------------------------------------------------------------- NOVATO, Kalifornien, 2011-07-27 01:10 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP), kundigte heute an, dass mittags (Eastern Standard Time) am 26. Juli eine Telefonkonferenz und ein Webcast abhalten wird, um Erklarungen uber die positiven Ergebnisse der klinischen RP103 Phase-III-Studie abzugeben. Einwahlnummer fur U ...
  
  
• DGAP-News: Raptor Pharmaceutical erreicht primaren Endpunkt in seiner klinischen Phase-III-Studie zur Untersuchung von DR Cysteamin fur nephropathische Cystinose
  Raptor Pharmaceutical Corp. 26.07.2011 09:17 --------------------------------------------------------------------------- NOVATO, Kalif., 2011-07-26 09:17 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) gab heute bekannt, dass seine klinische Phase-III-Studie zur Untersuchung von Delayed Release bzw. DR Cysteamin zur Behandlung von nephropathischer Cystinose, bekannt als Studienmedikament RP103 ('RP103'), den primaren Endpunkt hinsichtlich d ...
  
  
• DGAP-News: Raptor Pharmaceutical to Host Conference Call and Webcast to Discuss Phase 3 Clinical Trial Results on Tuesday, July 26, 2011 at Noon EDT
  Raptor Pharmaceutical Corp. 26.07.2011 03:24 --------------------------------------------------------------------------- NOVATO, Calif., 2011-07-26 03:24 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced today that they will host a conference call and webcast noon Eastern Time on July 26, 2011, to comment on the Company's positive Phase 3 RP103 clinical trial results. U.S/Canada Dial-in Number: +1 866.202.3109 International ...
  
  
• DGAP-News: Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 25.07.2011 12:30 --------------------------------------------------------------------------- NOVATO, Calif., 2011-07-25 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) today announced that its Phase 3 clinical trial of Delayed Release or DR Cysteamine, known as study drug RP103 ('RP103'), for the treatment of nephropathic cystinosis, met the primary endpoint of non-inferiority compared to Cystagon(r), immediate-r ...
  
  
• DGAP-News: Raptor Pharmaceutical hat die Benachrichtigung der Zulassung fur zwei Schwerpunkt-Patentanmeldungen erhalten, die ihr Cysteamine-Portfolio schutzen. Die Patente schutzen die Zusammensetzung und die Verfahren zur Anwendung.
  Raptor Pharmaceutical Corp. 07.07.2011 00:47 --------------------------------------------------------------------------- NOVATO, Kalif., 2011-07-07 00:47 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute bekannt gegeben, dass das United States Patent und Trademark Office ('USPTO') Benachrichtigungen der Zulassung fur zwei Patente herausgegeben hat, die die orale Form mit verzogerter Freisetzung von Cysteaminebitartrat ('DR Cysteamin ...
  
  
• DGAP-News: Raptor Pharmaceutical Receives Notices of Allowance for Two Key Patent Applications Protecting Its Cysteamine Portfolio
  Raptor Pharmaceutical Corp. 06.07.2011 12:30 --------------------------------------------------------------------------- Patents Claim Covers Composition and Methods of Use NOVATO, Calif., 2011-07-06 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that the United States Patent and Trademark Office ('USPTO') has issued Notices of Allowance for two patents covering the Company's delayed-release oral formulation of cysteamine ...
  
  
• DGAP-News: Raptor Pharmaceutical Corp.
  Raptor Pharmaceutical Corp. 07.06.2011 00:32 --------------------------------------------------------------------------- Raptor Pharmaceutical aktualisiert Informationen zur klinischen Phase-III-Studie Klinische Studie zur Behandlung von nephropathischer Cystinose mit DR Cysteamin Veroffentlichung der Studiendaten wird fuer Juli 2011 erwartet NOVATO, Kalif., 2011-06-07 00:10 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute bekan ...
  
  
• DGAP-News: Raptor Pharmaceutical Provides Update on Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 06.06.2011 12:30 --------------------------------------------------------------------------- Data From Trial Expected to be Released July 2011 NOVATO, Calif., 2011-06-06 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced that on June 3 the last clinical trial patient visits were completed and final data analysis will commence this week on the Phase 3 clinical trial of its delayed-release oral formu ...
  
  
• DGAP-News: Raptor Pharmaceutical ernennt Kathlene L. Powell
  Raptor Pharmaceutical Corp. 13.04.2011 23:10 --------------------------------------------------------------------------- zum Vice President, Quality Operations NOVATO, Kalifornien, 2011-04-13 23:10 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' oder das 'Unternehmen') (Nasdaq:RPTP) hat heute bekanntgegeben, dass das Unternehmen Kathlene L. Powell auf die neu geschaffene Position des VP, Quality Operations, berufen hat. Powell wird den Bereich Quality Assurance and Quality C ...
  
  
• DGAP-News: Raptor Pharmaceutical nimmt drei weitere Fuehrungskraefte aus dem Bereich Biopharmaceuticals in den Aufsichtsrat auf
  Raptor Pharmaceutical Corp. 13.04.2011 22:57 --------------------------------------------------------------------------- Die Erfahrung in der Produktentwicklung und Vermarktung bringt Raptors DR Cysteamin-Programm voran und traegt zur weiteren Wachstumsentwicklung bei NOVATO, Kalif., 2011-04-13 22:57 CEST (GLOBE NEWSWIRE) -- Die Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute die Veraenderung des Aufsichtsrats durch die Ernennung von Suzanne L. Bruhn, P ...
  
  
• DGAP-News: Raptor Pharmaceutical Adds Three Biopharmaceutical Leaders to Its Board of Directors
  Raptor Pharmaceutical Corp. 13.04.2011 12:30 --------------------------------------------------------------------------- Experience in Product Development and Commercialization to Enhance Raptor's DR Cysteamine Program and Additional Growth Endeavors NOVATO, Calif., 2011-04-13 12:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced today the appointments of Suzanne L. Bruhn, Ph.D., Vijay B. Samant and Timothy P. Walbert to the Company' ...
  
  
• DGAP-News: Raptor Pharmaceutical Appoints Kathlene L. Powell Vice President, Quality Operations
  Raptor Pharmaceutical Corp. 13.04.2011 09:30 --------------------------------------------------------------------------- NOVATO, Calif., 2011-04-13 09:30 CEST (GLOBE NEWSWIRE) -- Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), announced today that it has named Kathlene L. Powell to the newly created position of VP, Quality Operations. Ms. Powell will be responsible for overseeing Quality Assurance and Quality Control (QA/QC) for Raptor, as well as leading Chemistry an ...
  
  
• DGAP-News: Raptor Pharmaceutical nimmt fuenf weitere Patienten in die Phase-III-Schluesselstudie zur Pruefung von DR Cysteamin als Behandlungsmoglichkeit bei nephropathischer Cystinose auf
  Raptor Pharmaceutical Corp. 16.02.2011 10:13 --------------------------------------------------------------------------- Die Veroffentlichung der Studiendaten wird fuer das zweite Quartal 2011 erwartet NOVATO, Kalif., 2011-02-16 10:13 CET (GLOBE NEWSWIRE) --Die Raptor Pharmaceutical Corp. ('Raptor' oder 'das Unternehmen') (Nasdaq:RPTP) gab heute die Wiederaufnahme des Patienteneinschlussverfahrens in ihre klinische Phase-III-Studie zur Pruefung ihrer patentrechtlich geschuetzten oralen Cyste ...
  
  
• DGAP-News: Raptor Pharmaceutical to Enroll Five Additional Patients in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 15.02.2011 09:34 --------------------------------------------------------------------------- Data From Trial Expected to be Released in Second Quarter of 2011 NOVATO, Calif., 2011-02-15 09:34 CET (GLOBE NEWSWIRE) --Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced it has reopened enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ('DR Cysteamine') in patients wi ...
  
  
• DGAP-News: Pharmaceutical beendet Einschluss in klinische Phase-III-Schluesselstudie zur Pruefung von DR Cysteamin zur Therapie der nephropathischen Cystinose
  Raptor Pharmaceutical Corp. 25.01.2011 03:56 --------------------------------------------------------------------------- Es wird erwartet, dass ueber 30 Patienten die achtwochige Studie abschliessenNOVATO, Kalif., 25. Jan. 2011 (GLOBE NEWSWIRE) - Die Raptor Pharmaceutical Corporation ('Raptor' oder 'das Unternehmen') (Nasdaq: RPTP) gab heute den Abschluss der Patientenaufnahme in ihre klinische Phase-III-Studie zur Pruefung ihrer proprietaeren oralen Cysteamin-Bitartrat-Formulierung mit verzo ...
  
  
• DGAP-News: Raptor Pharmaceutical Completes Enrollment in Pivotal Phase 3 Clinical Trial of DR Cysteamine for the Potential Treatment of Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 24.01.2011 12:30 --------------------------------------------------------------------------- Over 30 Patients Expected to Complete Eight-Week Study Protocol NOVATO, Calif., 2011-01-24 12:30 CET (GLOBE NEWSWIRE) --Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP), today announced it has completed enrollment in its Phase 3 clinical trial of its proprietary delayed-release oral formulation of cysteamine bitartrate ('DR Cysteamine') in patients wit ...
  
  
• DGAP-News: Raptor Pharmaceutical Hires Patrick Reichenberger to Lead Commercial Development of DR Cysteamine for Nephropathic Cystinosis
  Raptor Pharmaceutical Corp. 10.01.2011 12:30 --------------------------------------------------------------------------- Contracts in Place for Cambrex Corporation and Patheon, Inc. to Manufacture Active Pharmaceutical Ingredient and Commercial Product, Respectively NOVATO, Calif., 2011-01-10 12:30 CET (GLOBE NEWSWIRE) --Raptor Pharmaceutical Corp. ('Raptor' or the 'Company') (Nasdaq:RPTP) announced today the appointment of Patrick Reichenberger to the newly created position of Vice Preside ...